Suppr超能文献

基于真实世界数据评估实现 HIV 病毒抑制所需的抗逆转录病毒药物依从性水平。

Antiretroviral Adherence Level Necessary for HIV Viral Suppression Using Real-World Data.

机构信息

Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, GA.

Health Analytics, Research, and Reporting Department, Walgreen Co., Deerfield, IL.

出版信息

J Acquir Immune Defic Syndr. 2019 Nov 1;82(3):245-251. doi: 10.1097/QAI.0000000000002142.

Abstract

BACKGROUND

A benchmark of near-perfect adherence (≥95%) to antiretroviral therapy (ART) is often cited as necessary for HIV viral suppression. However, given newer, more effective ART medications, the threshold for viral suppression may be lower. We estimated the minimum ART adherence level necessary to achieve viral suppression.

SETTINGS

The Patient-centered HIV Care Model demonstration project.

METHODS

Adherence to ART was calculated using the proportion of days covered measure for the 365-day period before each viral load test result, and grouped into 5 categories (<50%, 50% to <80%, 80% to <85%, 85% to <90%, and ≥90%). Binomial regression analyses were conducted to determine factors associated with viral suppression (HIV RNA <200 copies/mL); demographics, proportion of days covered category, and ART regimen type were explanatory variables. Generalized estimating equations with an exchangeable working correlation matrix accounted for correlation within subjects. In addition, probit regression models were used to estimate adherence levels required to achieve viral suppression in 90% of HIV viral load tests.

RESULTS

The adjusted odds of viral suppression did not differ between persons with an adherence level of 80% to <85% or 85% to <90% and those with an adherence level of ≥90%. In addition, the overall estimated adherence level necessary to achieve viral suppression in 90% of viral load tests was 82% and varied by regimen type; integrase inhibitor- and nonnucleoside reverse transcriptase inhibitor-based regimens achieved 90% viral suppression with adherence levels of 75% and 78%, respectively.

CONCLUSIONS

The ART adherence level necessary to reach HIV viral suppression may be lower than previously thought and may be regimen-dependent.

摘要

背景

通常认为,抗逆转录病毒疗法(ART)的近乎完美依从率(≥95%)是实现 HIV 病毒抑制所必需的。然而,鉴于新型、更有效的 ART 药物,病毒抑制的阈值可能更低。我们估计了实现病毒抑制所需的最低 ART 依从水平。

设置

以患者为中心的 HIV 护理模型示范项目。

方法

在每次病毒载量检测结果前的 365 天内,采用覆盖日比例法计算 ART 依从性,并将其分为 5 个类别(<50%、50%至<80%、80%至<85%、85%至<90%和≥90%)。采用二项回归分析确定与病毒抑制相关的因素(HIV RNA<200 拷贝/ml);人口统计学、覆盖日比例类别和 ART 方案类型是解释变量。广义估计方程采用可交换工作相关矩阵,以考虑到个体内部的相关性。此外,还使用概率回归模型来估计实现 90%的 HIV 病毒载量检测抑制所需的依从水平。

结果

在依从水平为 80%至<85%或 85%至<90%的患者与依从水平≥90%的患者之间,病毒抑制的调整后比值比没有差异。此外,实现 90%的病毒载量检测抑制所需的总体估计依从水平为 82%,且因方案类型而异;基于整合酶抑制剂和非核苷类逆转录酶抑制剂的方案分别需要 75%和 78%的依从水平来实现 90%的病毒抑制。

结论

实现 HIV 病毒抑制所需的 ART 依从水平可能低于先前的设想,且可能取决于方案类型。

相似文献

1
Antiretroviral Adherence Level Necessary for HIV Viral Suppression Using Real-World Data.
J Acquir Immune Defic Syndr. 2019 Nov 1;82(3):245-251. doi: 10.1097/QAI.0000000000002142.
3
Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen.
Int J Antimicrob Agents. 2018 Oct;52(4):492-499. doi: 10.1016/j.ijantimicag.2018.07.001. Epub 2018 Sep 13.
9
Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes.
Ann Intern Med. 2007 Apr 17;146(8):564-73. doi: 10.7326/0003-4819-146-8-200704170-00007.
10
The Medication Possession Ratio as a Predictor of Longitudinal HIV-1 Viral Suppression.
Ann Pharmacother. 2023 Nov;57(11):1264-1272. doi: 10.1177/10600280231156624. Epub 2023 Mar 22.

引用本文的文献

1
MK-8527 is a novel inhibitor of HIV-1 reverse transcriptase translocation with potential for extended-duration dosing.
PLoS Biol. 2025 Aug 26;23(8):e3003308. doi: 10.1371/journal.pbio.3003308. eCollection 2025 Aug.
5
Sustained HIV Viral Suppression 18 Months After the Last Dose of Long-acting Cabotegravir/Rilpivirine: A Case Report.
Open Forum Infect Dis. 2025 Jul 3;12(7):ofaf399. doi: 10.1093/ofid/ofaf399. eCollection 2025 Jul.
8
Post-COVID-19 Medication Adherence Among HIV/AIDS Patients in Belize: A Case for Consolidating Education and Monitoring.
AIDS Res Treat. 2025 May 25;2025:5552340. doi: 10.1155/arat/5552340. eCollection 2025.
10

本文引用的文献

2
Risk Factors, Health Care Resource Utilization, and Costs Associated with Nonadherence to Antiretrovirals in Medicaid-Insured Patients with HIV.
J Manag Care Spec Pharm. 2018 Oct;24(10):1040-1051. doi: 10.18553/jmcp.2018.17507. Epub 2018 Jun 7.
4
The Role of HIV-1 Drug-Resistant Minority Variants in Treatment Failure.
J Infect Dis. 2017 Dec 1;216(suppl_9):S847-S850. doi: 10.1093/infdis/jix430.
5
Coming full circle in the measurement of medication adherence: opportunities and implications for health care.
Patient Prefer Adherence. 2017 Jun 2;11:1009-1017. doi: 10.2147/PPA.S127131. eCollection 2017.
7
Patient-Reported Barriers to Adherence to Antiretroviral Therapy: A Systematic Review and Meta-Analysis.
PLoS Med. 2016 Nov 29;13(11):e1002183. doi: 10.1371/journal.pmed.1002183. eCollection 2016 Nov.
8
Suboptimal Adherence to Combination Antiretroviral Therapy Is Associated With Higher Levels of Inflammation Despite HIV Suppression.
Clin Infect Dis. 2016 Dec 15;63(12):1661-1667. doi: 10.1093/cid/ciw650. Epub 2016 Sep 22.
9
Antiretroviral Therapy for the Prevention of HIV-1 Transmission.
N Engl J Med. 2016 Sep 1;375(9):830-9. doi: 10.1056/NEJMoa1600693. Epub 2016 Jul 18.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验